Ultragenyx Pharmaceutical (RARE)

• Market cap: $3.07B
• 1 day: -2.95%
• 5 days: -3.25%
• 1 month: -7.38%
• 3 months: 9.41%
• 6 months: -11.96%
• Year to date: -22.58%
• 1 year: -29.4%
• 5 years: -71.76%
• 10 years: -67.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,294